Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03123289 · ClinicalTrials.gov registry record · Phase 2
Novel Gallium 68 Citrate in Orthopedic Infections
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03123289 is a Phase 2 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 1 participants.
The verdict
NCT03123289, a Phase 2 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
In the proposed study, our aim is to evaluate the uptake of 68Gallium-citrate in patients with failed joint prosthesis and compare it with that of conventional 18fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scan. We will perform PET/CT scan with 68Gallium citrate and 18F-FDG in subjects with failed hip or knee prosthesis. Both 68Gallium-citrate and 18F-FDG scans, done within 24-48 hours from each other, will be performed within 4 weeks before surgical evaluation/revision of the hardware.
Interventions
- DRUG 68-Gallium citrate PET/CT scan
- DRUG 18F FDG PET/CT scan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-03-06 |
| Est. Completion | 2020-10-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03123289
The ClinicalTrials.gov registry entry for NCT03123289 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 68-Gallium citrate PET/CT scan is the first listed.
NCT03123289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03123289 about?
NCT03123289 is a clinical study titled "Novel Gallium 68 Citrate in Orthopedic Infections". In the proposed study, our aim is to evaluate the uptake of 68Gallium-citrate in patients with failed joint prosthesis and compare it with that of conventional 18fluorine-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scan. We will perform PET/CT scan with 68G...
What is the current status of trial NCT03123289?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-03-06. Estimated completion is 2020-10-14.
What interventions are being tested in trial NCT03123289?
The interventions under investigation include: 68-Gallium citrate PET/CT scan (DRUG), 18F FDG PET/CT scan (DRUG).
Who is sponsoring clinical trial NCT03123289?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.